Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

VERTEX PH Form 4 May 18, 2011	ARMACEUTIC	CALS INC	C/MA								
FORM	4 UNITED	S SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549				-	PPROVAL 3235-0287				
Check this if no longe subject to Section 16 Form 4 or Form 5 obligations may contin <i>See</i> Instruct 1(b).	 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section a) (b) of the Investment Company Act of 1940 							Expires: Estimated burden hou response	urs per		
(Print or Type Re	esponses)										
1. Name and Ad Kearney Terr	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
(Last) C/O VERTE PHARMACE INCORPORA ST.	x	Middle) VERLY		of Earliest T Day/Year) 2011	ransactior	I	X Director Officer (giv below)		% Owner her (specify		
			4. If Amendment, Date Original Filed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 					
	E, MA 02139						Person	wore than one R	eporting		
(City)	(State)	ate) (Zip) Table I - Non-Derivative Securities Acquired, Disposed						of, or Beneficially Owned			
	. Transaction Date Month/Day/Year)	2A. Deem Execution any (Month/Da	Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3,	(A) or f of (D) 4 and 5) (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Repo	rt on a separate line	e for each cl	ass of sec	urities bene	ficially ov	ned directly	y or indirectly.				
					infor requi	mation co red to res	espond to the colle ntained in this form pond unless the fo rently valid OMB co	n are not rm	SEC 1474 (9-02)		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

number.

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of TransactionDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount o Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Share
Stock Option	\$ 56.99	05/17/2011		А	30,000	08/17/2011 <u>(1)</u>	05/16/2021	Common Stock	30,000
Reporting Owners									

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

neporting Owners

Reporting Owner Name / Address		Relationships				
		Director	10% Owner	Officer	Other	
Kearney Terrence C C/O VERTEX PHARMACEUTICALS INCO 130 WAVERLY ST. CAMBRIDGE, MA 02139	ORPORATED	Х				
Signatures						
Kenneth S. Boger, 05/ Attorney-In-Fact	18/2011					

Signature of Reporting Person **Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 05/17/2011.

Date

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.